Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
78 hedge funds and large institutions have $460M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 25 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
11% less funds holding
Funds holding: 88 → 78 (-10)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
40% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 25
44% less capital invested
Capital invested by funds: $822M → $460M (-$363M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$28.6M |
| 2 |
DM
Deerfield Management
New York
|
+$14.9M |
| 3 |
BlackRock
New York
|
+$12.2M |
| 4 |
O
OrbiMed
New York
|
+$12M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$31.2M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$28.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.4M |
| 4 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$10.5M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$10K | -266 | Closed |
|
|
QT
102
Quantbot Technologies
New York
| – | -$5K | -153 | Closed |
|
|
TRCT
103
Tower Research Capital (TRC)
New York
| – | -$2K | -51 | Closed |
|
DCPH Hedge Fund Activity: Q4 2018 in Review
78 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2018, worth a combined $460M — down 44% from $822M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of DCPH and 15 opened new positions — a net loss of 10 holders — while 19 trimmed existing stakes and 31 added.
The largest buyer was Millennium Management, adding an estimated $28.6M. The largest seller was Polar Capital, exiting entirely with an estimated $31.2M sold.
- 78 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2018, down from 88 in Q3 2018.
- Funds reported $460M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 44% quarter-over-quarter.
- 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 25 closed out, a net change of -10 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Millennium Management, an estimated $28.6M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Polar Capital, an estimated $31.2M sold.
Based on aggregated 13F filings for Q4 2018.